Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5104915 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL5117318 | 0.93 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL5117324 | 0.93 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL6610559 | 0.92 | PARP1 (0.37) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL6610557 | 0.92 | PARP1 (0.37) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL5116104 | 0.86 | HSD11B1 (0.37) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL5116099 | 0.86 | HSD11B1 (0.37) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL22589283 | 0.79 | CHRM2 (0.51) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL7672577 | 0.77 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL22589355 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423384-B1 | PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2007-05-23 | — | — | EP | disclosed |
| US-20050176740-A1 | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor | SMITHKLINE BEECHAM CORPORATION | 2005-08-11 | — | — | US | disclosed |
| EP-1492568-A1 | CANCER TREATMENT METHOD COMPRISING ADMINISTRATION OF AN ERB-FAMILY INHIBITOR AND A RAF AND/OR RAS INHIBITOR | SmithKline Beecham Corporation (US) | 2005-01-05 | — | — | EP | disclosed |
| EP-1423384-A1 | PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003086467-A1 | CANCER TREATMENT METHOD COMPRISING ADMINISTERING AN ERB-FAMILY INHIBITOR AND A RAF AND/OR RAS INHIBITOR | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003022840-A1 | PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176740-A1 | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor | BRAF, KRAS, NRAS | SMN1; SMN2 4665/4885NPC1 3636/4885RAB9A 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.